AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03121482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HFNC
Description: Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%
Study NCT03121482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%
Study NCT03121482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIV
Description: Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cm H2O with FiO2 adjusted to obtain SpO2 ≥ 92%
Study NCT01453933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir
Description: Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)
Study NCT04306666 — intervention group
Intervention type: OTHER
Intervention: Regional anesthesia
Description: Injection of local anesthetics by a regional anesthesia named Walant block (Wide Awak Local anesthesia No Tourniquet)or by axillary brachial plexus block.
Study NCT01376895 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROJECT POWER
Description: POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.
Study NCT01376895 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Power Health
Description: Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
Study NCT03882853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conservative exercise group
Description: The group will be thought exercise series which based on recommendations published on October 2016 by UK national osteoporosis foundation.Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.
Study NCT03882853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative exercise group
Description: The group will be thought exercise series which based on recommendations published on October 2016 by UK national osteoporosis foundation.Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.
Study NCT03882853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tree pose added exercise group
Description: The group will be thought exercise series which will be based on recommendations which is published on October 2016 by UK national osteoporosis foundation, also be taught tree pose of yoga. Handouts including pictures and narrations of the exercises will be given to patients. Patients would be encouraged to perform the exercises 5 days a week. A diary will be given to note the days exercises completed.
Study NCT01503892 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Metanx
Description: Metanx- one tablet twice daily for twelve months
Study NCT01503892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo- one tablet twice daily for twelve months.
Study NCT03749213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients with EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer which can be potentially radical treated by surgery are arranged to receive Icotinib with a dose of 125 mg three times per day orally for 8 weeks as neoadjuvant therapy before surgery and for 2 years as adjuvant therapy or till progressive disease or unaccepted toxicity.
Study NCT06298760 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Knee Massage With Black Cumin Oil Group:
Description: The patients received a knee massage with black cumin oil once a week for approximately 30 minutes for 6 weeks.
Study NCT06298760 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Foot Reflexology Group With Black Cumin Oil
Description: The patients underwent foot reflexology with black cumin oil once a week for approximately 40 minutes for 6 weeks.
Study NCT06298760 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Applications were made with vaseline
Study NCT00333424 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine
Description: 6mg pHIS-HIV-AE at weeks 0, 4 and 8; 3 x 10e8 pfu/mL rFPV-HIV-AE at week 12
Study NCT01878227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coenzyme A
Description: Coenzyme A 400mg per day
Study NCT01878227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 200mg
Description: Fenofibrate 200mg per day
Study NCT03858569 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active management of third stage of labor
Description: Active management of the third stage of the labor will be done administering oxytocin and cord traction.
Study NCT01856855 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy with Integrated Boost
Description: SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
Study NCT02781415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional Acupuncture Session
Description: Skin disinfection was made by an antiseptic solution in the sites of insertion and sterile acupuncture needles were used (0.25 x 0.5 mm).~Patients were installed in a seated position and needles were inserted perpendicularly through the skin to a depth of 1 - 2 cm until the De Qi was achieved.~The DeQi corresponds to a feeling of numbness and tingling within the range of acupoint, The insertion sites are represented by the urinary bladder meridian points to the side of the pain (UB21, UB22, UB23, UB24, UB26, UB45, UB46, UB47, UB48 and UB49).
Study NCT02781415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Titration
Description: Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).~An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.~A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal.
Study NCT01515488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-initiated triage
Description: Nurse-assisted triage for obtaining medical history and presenting problem(s)
Study NCT01515488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-triage kiosk
Description: Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
Study NCT04682249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Chemotherapy
Description: Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)
Study NCT04682249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab
Study NCT04682249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib
Study NCT00557323 — intervention group
Intervention type: DRUG
Intervention: Lanthanum carbonate
Study NCT02566876 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixture of three Bifidobacteria
Description: This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
Study NCT02566876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mixture of three Bifidobacteria
Description: This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
Study NCT03383068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose 100 MG
Description: for metformin uneffective subjects, using acarbose for 3 months
Study NCT03383068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: for metformin uneffective subjects, using Exenatide for 3 months
Study NCT03383068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: for metformin uneffective subjects, using Orlistatfor 3 months
Study NCT03383068 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: metformin effective subjects,act as control group
Study NCT01619813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, Reolysin and Prednisone
Description: Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.
Study NCT01619813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel and Prednisone
Description: Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
Study NCT00688623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus 5 mg tablets were supplied in blister packs
Study NCT00058188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given orally
Study NCT00058188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: Given orally
Study NCT00058188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium gluconate
Description: Given orally
Study NCT00058188 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium gluconate
Description: Given orally
Study NCT01089062 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MAP0004
Description: 1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
Study NCT00058188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: Given IV
Study NCT02394990 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Violence Brief Intervention
Description: Strategies for self assessment of consequences of violent behavior and strategies for avoidance of violence
Study NCT02394990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ABI
Study NCT00611767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiopental
Description: A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
Study NCT00611767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
Study NCT03289052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Volyme
Description: Subcutis injection
Study NCT04308954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]flumazenil
Description: \[18F\]flumazenil is a PET radiopharmaceutical that can be used to determine gamma-aminobutyric acid (GABA(A)) receptor density.
Study NCT03466671 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TTA-121
Description: A nove intranasal spray of oxytocin and placebo
Study NCT03561168 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Change in plan of care based on MRI results
Description: Study subjects have received the intervention if the results of their MRI either 1. provide an etiology for said MRI's indication or 2. the patient received a change in plan of care based on MRI results.
Study NCT02323308 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Study NCT04825249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: traditional suture bridge technique
Description: (A) Limbs of the sutures from the medial anchor were passed through torn tendon (B) the suture limbs were tied in a horizontal mattress suture pattern (C) the lateral row pressed the free tails of the knotted line on the greater tubercle of the humerus (D) the effect after completion of the TSB technique
Study NCT04825249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified suture bridge technique
Description: (A) Limbs of the sutures from the medial anchor and 2 tendon sutures were passed through the same position of torn tendon (B) the lateral row pressed free tails of the two tendon lines on the greater tubercle of the humerus (C) after examination of sufficient tension and stable fixation, sutures of medial row was knotted (D) the effect after completion of the MSB technique
Study NCT01493934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injection of 6-DIG
Description: Unique injection dose of 92.5 MBq
Study NCT01493934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: injection of 6-DIG
Description: Unique injection dose of 92.5 MBq
Study NCT02985489 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olimel Parenteral Nutrition
Description: Olimel 5.7% with electrolytes
Study NCT00063388 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
Study NCT02621645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early selective reduction of TRAP mass
Description: Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle
Study NCT02621645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late selective reduction of TRAP mass
Description: Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.
Study NCT01089062 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IV Placebo (Saline)
Description: IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
Study NCT02621645 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle
Study NCT02621645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle
Study NCT02621645 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber
Study NCT01744041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Interpersonal Psychotherapy
Description: This intervention consists of a brief psychotherapeutic intervention, Interpersonal Psychotherapy, during pregnancy. Interpersonal Psychotherapy focuses on improving social relationships and interpersonal communication to improve mood. The postpartum phase also utilizes developmentally appropriate strategies to improve the mother-infant relationship.
Study NCT01744041 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: This intervention consists of personalized referrals to specialty mental health providers, spiritual counselors, or other needed social services. It includes some non-specific supportive techniques delivered primarily via telephone.
Study NCT00610207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)
Description: Surgical placement of the Surgisis AFP is performed under general anesthesia
Study NCT02017457 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusion
Description: On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes (ideally on day 1 but in case of organizational problems, DLI can be administered until day 5) .~* Patients with a sibling donor will receive:~* 5x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6~* Patients with an unrelated donor will receive:~* 1x10exp7 CD3+/kg on day 1 of cycle 2~* 5x10exp7 CD3+/kg on day 1 of cycle 4~* 10x10exp7 CD3+/kg on day 1 of cycle 6
Study NCT02017457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: * Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.~* Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.~All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission.~In case of stable disease or partial response, Azacytidine will be continued until progression.~In case of disease progression after cycle 6, Azacytidine will be stopped.
Study NCT02465489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone extended release
Description: Deferiprone 1000 mg extended release tablet formulation
Study NCT01089062 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Inhaler
Description: Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
Study NCT02465489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferiprone immediate release
Description: Ferriprox (deferiprone) 500 mg immediate release tablet formulation
Study NCT04364906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regional anesthesia
Description: The effects of QLB 2, 3 interfascial plane blocks on post-operative analgesia after cesarean section surgery
Study NCT02572804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural
Description: Patients in this group will have an epidural inserted in a standard fashion, prior to the induction of anesthesia. These will be infused with 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response. Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
Study NCT02572804 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus Sheath Catheters
Description: Patients in this group will have surgically inserted rectus sheath catheters (bilaterally), immediately prior to closure of the anterior abdominal wall. These will be infused with 0.125% Bupivicaine at 5mls an hour at a standard rate.Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
Study NCT03003130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: Intradermal injection
Study NCT03003130 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane
Description: Intradermal injection
Study NCT02382965 — intervention group
Intervention type: DEVICE
Intervention: transcranial focused ultrasound
Study NCT02885272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT scans
Study NCT02885272 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT02885272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo standard of care MRI
Study NCT02885272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scans